Literature DB >> 28261855

INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.

Haiwen Chen1, Hongliang Li1, Qi Chen1.   

Abstract

Inositol polyphosphate 4-phosphatase B (INPP4B) has been identified as a tumour suppressor in different human cancers. However, the role of INPP4B in the angiogenesis of human prostate cancer cells remains unclear. In this study, we first compared the expression of INPP4B between prostate cancer tissues and tumour-adjacent normal prostate tissues using immunohistochemistry. Then, we explored the role of INPP4B in prostate cancer progression via transfection of a Flag-INPP4B plasmid into PC3 and DU145 cells in vitro and in vivo. Our results showed that reduced INPP4B staining was significantly correlated with the tumour-node-metastasis stage. Moreover, transfection with Flag-INPP4B plasmid suppressed the migration and invasion of prostate cancer cells through inactivating the PI3K/Akt signalling pathway, at the same time decreased vascular endothelial growth factor secretion and suppressed human umbilical vein endothelial cells proliferation and tube formation. Futhermore, it was also found that INPP4B could inhibit tumour growth and angiogenesis in vivo. Altogether, our results supported that INPP4B acted as a tumour suppressor in human prostate cancer, and provided insights into development of a targeted therapy for this disease.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  INPP4B; angiogenesis; human prostate cancer; invasion; migration

Mesh:

Substances:

Year:  2017        PMID: 28261855     DOI: 10.1111/1440-1681.12745

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

Review 1.  The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.

Authors:  Boris Y Shorning; Manisha S Dass; Matthew J Smalley; Helen B Pearson
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

2.  A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.

Authors:  Chenhao Zhou; Yue Zhao; Yirui Yin; Zhiqiu Hu; Manar Atyah; Wanyong Chen; Zhefeng Meng; Huarong Mao; Qiang Zhou; Weiguo Tang; Pengcheng Wang; Zhanming Li; Jialei Weng; Christiane Bruns; Marie Popp; Felix Popp; Qiongzhu Dong; Ning Ren
Journal:  Int J Biol Sci       Date:  2019-08-22       Impact factor: 6.580

3.  Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells.

Authors:  Youliang Wu; Delong Meng; Xin Xu; Junjun Bao; Yexiang You; Yanjun Sun; Yongxiang Li; Dengqun Sun
Journal:  BMC Cancer       Date:  2021-04-20       Impact factor: 4.430

Review 4.  Targeting DNA repair pathway in cancer: Mechanisms and clinical application.

Authors:  Manni Wang; Siyuan Chen; Danyi Ao
Journal:  MedComm (2020)       Date:  2021-12-07

5.  INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway.

Authors:  Xiaoming Sun; Yani Chen; Xiaoyang Tao; Wenzi Zhang; Xinyu Wang; Xianhui Wang; Zhihua Ruan; Zhuo Chen
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

6.  Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Authors:  Anders E Berglund; Robert J Rounbehler; Travis Gerke; Shivanshu Awasthi; Chia-Ho Cheng; Mandeep Takhar; Elai Davicioni; Mohammed Alshalalfa; Nicholas Erho; Eric A Klein; Stephen J Freedland; Ashley E Ross; Edward M Schaeffer; Bruce J Trock; Robert B Den; John L Cleveland; Jong Y Park; Jasreman Dhillon; Kosj Yamoah
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-10-26       Impact factor: 5.554

7.  Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3.

Authors:  Surendra Chaurasiya; Wanfu Wu; Anders M Strom; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.